A series of pentapeptides, based on Bu-His(6)-DPhe(7)-Arg(8)-Trp(9)-Gly(10)-NH(2) and modified at the Arg(8) position, was prepared and pharmacologically characterized. Peptides containing either cyanoguanidine or acylguanidine, two substantially less basic arginine surrogates, were found to retain the agonist activity of the parent peptide at both hMC1R and hMC4R. This study unequivocally shows that the positive charge of Arg(8) is not essential for efficient interactions of our pentapeptide with both hMC1R and hMC4R.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0960-894x(02)00459-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ψ and χ Angle Constrains at the C-Terminus Trp Position of the Melanotropin Tetrapeptide Ac-His-d-Phe-Arg-Trp-NH Lead to Potent and Selective Agonists at hMC1R and hMC4R.
J Med Chem
May 2023
Department of Chemistry and Biochemistry, The University of Arizona, Tucson, Arizona 85721, United States.
Melanocortin receptors (MCRs) are a family of G protein-coupled receptors that regulate important physiological functions. Yet, drug development targeting MCRs is hindered by potential side effects due to a lack of receptor subtype-selective ligands with bioavailability. Here, we report novel synthetic pathways to introduce Ψ and χ angle constraints at the C-terminus Trp position of the nonselective prototype tetrapeptide agonist Ac-His-d-Phe-Arg-Trp-NH.
View Article and Find Full Text PDFMelanocortin 1 Receptor Agonists Based on a Bivalent, Bicyclic Peptide Framework.
J Med Chem
July 2021
Institute for Molecular Bioscience, Australian Research Council Centre of Excellence for Innovations in Peptide and Protein Science, The University of Queensland, Brisbane, QLD 4072, Australia.
We have designed a new class of highly potent bivalent melanocortin receptor ligands based on the nature-derived bicyclic peptide sunflower trypsin inhibitor 1 (SFTI-1). Incorporation of melanotropin pharmacophores in each of the two turn regions of SFTI-1 resulted in substantial gains in agonist activity particularly at human melanocortin receptors 1 and 3 (hMC1R/hMC3R) compared to monovalent analogues. In binding and functional assays, the most potent molecule, compound , displayed low picomolar agonist activity at hMC1R (pEC > 10.
View Article and Find Full Text PDFDevelopment of hMC1R Selective Small Agonists for Sunless Tanning and Prevention of Genotoxicity of UV in Melanocytes.
J Invest Dermatol
July 2021
Department of Dermatology, University of Cincinnati, Cincinnati, Ohio, USA. Electronic address:
Article Synopsis
- Activation of the human melanocortin 1 receptor (hMC1R) by α-melanocortin plays a crucial role in regulating skin color and protecting against UV damage by enhancing DNA repair and antioxidant defenses.
- Researchers developed modified tetra- and tripeptide agonists that are more effective and selective for hMC1R than existing α-melanocortin analogs, leading to improved skin protection.
- One standout tripeptide, LK-514, shows exceptional selectivity for hMC1R and promotes pigmentation in skin models, suggesting potential uses in preventing skin cancer and treating conditions like vitiligo.
A Venomics Approach Coupled to High-Throughput Toxin Production Strategies Identifies the First Venom-Derived Melanocortin Receptor Agonists.
J Med Chem
August 2020
Université Paris Saclay, CEA, Département Médicaments et Technologies pour la Santé, SIMoS, Gif-sur-Yvette 91191 France.
Animal venoms are rich in hundreds of toxins with extraordinary biological activities. Their exploitation is difficult due to their complexity and the small quantities of venom available from most venomous species. We developed a Venomics approach combining transcriptomic and proteomic characterization of 191 species and identified 20,206 venom toxin sequences.
View Article and Find Full Text PDFBinding, Thermodynamics, and Selectivity of a Non-peptide Antagonist to the Melanocortin-4 Receptor.
Front Pharmacol
June 2018
Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Institute of Medical Physics and Biophysics, Berlin, Germany.
The melanocortin-4 receptor (MC4R) is a potential drug target for treatment of obesity, anxiety, depression, and sexual dysfunction. Crystal structures for MC4R are not yet available, which has hindered successful structure-based drug design. Using microsecond-scale molecular-dynamics simulations, we have investigated selective binding of the non-peptide antagonist MCL0129 to a homology model of human MC4R (hMC4R).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!